Sign up to save your podcasts
Or
Share Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Benchtalk 2025: Dyne Therapeutics' CSO Ron Batra describes the company's FORCE platform, and previews big trial scheduled in DMD and DM1 over the next year
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data.
View all episodes
By BiotechTV
5
44 ratings
He describes the science behind FORCE, which combines an antigen-binding fragment, a linker and, a payload. The company's DMD program will have a key trial readout before the end of this year, and DM1 will follow in 2026. Both programs could be filed for AA in 2026 with positive data.
More shows like BiotechTV - News
View all
Planet Money
30,626 Listeners
Odd Lots
1,863 Listeners
a16z Podcast
1,085 Listeners
The Readout Loud
325 Listeners
The Journal.
6,059 Listeners
Biotech 2050 Podcast
60 Listeners
All-In with Chamath, Jason, Sacks Friedberg
9,840 Listeners
Business Of Biotech
86 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
19 Listeners
ACQ2 by Acquired
260 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
497 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
2 Listeners
BioVenture VoiCes with Chris Garabedian
6 Listeners